A Phase 2 Safety and Efficacy Study Evaluating CS-101 in Participants With β-Thalassemia Major

Clinical trial NCT07489196 · NOT_YET_RECRUITING

Trial details

NCT number: NCT07489196
Sponsor: CorrectSequence Therapeutics Co., Ltd
Status: NOT_YET_RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

β-thalassemia Major

Start date: 2026-04-05
Primary completion: 2028-01-31
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.